Health9/18/2025The Guardian

A hi-tech health prediction that I could do without | Brief letters

A hi-tech health prediction that I could do without | Brief letters

The article discusses various topics, including a new AI tool that can predict a person's risk of 1,000 diseases, the potential resurrection of the dodo, and the suggestion to resurrect Homo neanderthalensis instead. The author, Sam White, expresses apprehension about the AI tool, stating that if it forecasts a high risk of a "horrible condition," it's unclear whether that would be good or bad news. The article also mentions a report from Patrick Cosgrove, who suggests that it would be better to resurrect Homo neanderthalensis, a more cooperative and less aggressive hominid, rather than the dodo. The article does not provide any additional details about the other topics mentioned, such as Donald Trump's state visit to Britain or the Saint George's flag.

Source: For the complete article, please visit the original source link below.

Related Articles

UK doctors guilty of sexual misconduct are not being struck off, research finds
🏥 Health7h ago1 min read

UK doctors guilty of sexual misconduct are not being struck off, research finds

CDC panel recommends multiple shots for measles, mumps, rubella and chickenpox instead of single vaccine
🏥 Health7h ago1 min read

CDC panel recommends multiple shots for measles, mumps, rubella and chickenpox instead of single vaccine

U.S. to Cut Out Nongovernmental Groups in Refocusing Health Aid
🏥 Health10h ago1 min read

U.S. to Cut Out Nongovernmental Groups in Refocusing Health Aid

Cost of private psychology soars in UK as practitioners turn away clients
🏥 Health11h ago1 min read

Cost of private psychology soars in UK as practitioners turn away clients

New York and Other States Form Health Bloc as Answer to Trump’s Policies
🏥 Health11h ago1 min read

New York and Other States Form Health Bloc as Answer to Trump’s Policies

NHS drug pricing is all about the art of the deal | Letter
🏥 Health13h ago1 min read

NHS drug pricing is all about the art of the deal | Letter